Merestinib dihydrochloride NEW
| Price | $108 |
| Package | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-03 |
Product Details
| Product Name: Merestinib dihydrochloride | CAS No.: 1206801-37-7 |
| Supply Ability: 10g | Release date: 2025/12/03 |
Product Introduction
Bioactivity
| Name | Merestinib dihydrochloride |
| Description | Merestinib dihydrochloride (LY2801653 dihydrochloride) is an orally available kinase inhibitor with antitumor activity that inhibits MET, AXL, RON, and MKNK1/2, and inhibits the growth of NTRK fusion-carrying tumors. |
| In vitro | Merestinib dihydrochloride is a potent, orally bioavailable c-Met inhibitor with a Ki value of 2 nM and significant antitumor activity. In addition, Merestinib dihydrochloride showed significant antitumor activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM) showed potent activity. Merestinib dihydrochloride affected MET pathway-dependent cell scattering and proliferation. In HGF-stimulated H460 cells, the mean IC50 value for Merestinib dihydrochloride on MET autophosphorylation was 35.2 nM, compared to 59.2 nM in S114 cells. Transfection of MET variants gave cells growth factor independence, and treatment with Merestinib dihydrochloride was able to inhibit the growth of these MET variant clones with IC50 values ranging from approximately 3-fold more potent (V1092I) to approximately 6-fold less potent (L1195V) compared to MET wild-type sequences. [1][2] |
| In vivo | Merestinib dihydrochloride showed significant antitumor effects in a MET-amplified xenograft model (MKN45), a MET autocrine model (U-87MG and KP4), and a MET overexpression model (H441), as well as in vivo vasculature normalization. As a type II ATP-competitive inhibitor, Merestinib dihydrochloride is a slow dissociating inhibitor of MET tyrosine kinase with a pharmacodynamic residence time (Koff) of 0.00132 min^-1 and a half-life (t1/2) of 525 min.Merestinib dihydrochloride treatment inhibited MET phosphorylation with a combined TED50 (50% targeted inhibitor dose) of 1.2 mg/kg and TED90 (90% targeted inhibitor dose) of 7.4 mg/kg.With Merestinib dihydrochloride (20 mg/kg), TFK-1 tumor growth was significantly lower than that of the control group. In addition, Merestinib dihydrochloride effectively inhibited the growth of intrahepatic and extrahepatic cholangiocarcinoma (CCC) xenograft tumors. [1][2] |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (5.28 mM), Sonication is recommended. DMSO : 80 mg/mL (127.91 mM), Sonication is recommended. |
| Keywords | TyrosineKinases | Tyrosine Kinases | TEK | TAMReceptor | TAM Receptor | MST1R | MKNK1/2 | MERTK | Merestinib | LY-2801653 Dihydrochloride | LY-2801653 | LY2801653 | LY 2801653 | HGFR | FLT3 | DDR1/2 | cMet/HGFR | c-Met | cMet | AXL |
| Inhibitors Related | Bemcentinib | Gilteritinib | Phosphocreatine disodium hydrate | Melamine | Sunitinib | Ruxolitinib | Sorafenib | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | L-Cystine | Afatinib | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $107.00/5mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-12-05 | |
| $0.00/1kg |
VIP2Y
|
Anhuyan (Hainan) Biotechnology Co., LTD
|
2025-06-10 | |
| $339.00/1kg |
VIP5Y
|
Shanghai UCHEM Inc.
|
2023-11-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY